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Does Recessive EKV Exist?
To the Editor:
We read the article by Terrinoni et al in the March issue of
the JID with much interest. In it, they described their finding
of a putative recessive GJB3 (connexin 31) mutation asso-
ciated with erythrokeratodermia variabilis (EKV). The exist-
ence of recessive skin disease-associated connexin
mutations would contribute significantly to our understand-
ing of gap junction biology. But we have a number of con-
cerns with the current report, that in our view, need to be
addressed before the existence of recessive EKV can be
accepted.
All data that are currently available with regard to gap
junction gene mutations associated with skin disease sug-
gest that the skin symptoms are caused by (trans-)dominant
effects of the mutations. Almost all skin disease-associated
mutations interfere with the transport of the mutant protein.
The mutant protein will, however, be incorporated into a gap
junction in the presence of a wild-type homotypic or het-
erotypic gap junction protein (Thomas et al, 2004). For
GJB2, mutations such as D66H, which is associated with
Vohwinkel’s syndrome, have been shown to interfere in a
trans-dominant manner with the expression of GJA1 (Rouan
et al, 2001; Thomas et al, 2004) and can lead to increased
sensitivity to apoptosis of keratinocytes (Bakirtzis et al,
2003). The dominant mutations in GJB3 that cause EKV
have been shown to be gain-of-function mutants that lead
to increased sensitivity to apoptosis of keratinocytes or in-
terfere with gap junction conductance (Di et al, 2002; Com-
mon et al, 2003; Rouan et al, 2003). Dominant mutations in
GJB6 can interfere with transport of the protein and impair
the assembly of heteromeric GJB6-containing gap junctions
(Common et al, 2002). At least one of the mutations asso-
ciated with KID syndrome, D50N, leads to a gain of function
of the gap junction (D. Gonzalez, personal communication,
2003). Dominant mutations associated with hearing loss
seem to traffic to the cell membrane but impair channel
function once inserted (Common et al, 2002; Marziano et al,
2003). They do not modify channel composition or lead to a
gain-of-function in contrast to the mutations associated
with skin disease. Recessive mutations associated with
hearing loss have been found mostly in GJB2, suggesting
that recessive missense or nonsense mutations in other
connexins that are expressed in the ear need not have
functional significance there with the possible exception of
GJA1 in which recessive mutations have been found in deaf
patients (Liu et al, 2001). These findings, however, have so
far not been replicated. The same observation may very well
apply to the skin. There is a previous report that describes a
recessive mutation in GJB3, L34P, and claims that it causes
EKV (Gottfried et al, 2002). The clinical data supplied are
scarce and, in our view, do not support the diagnosis of
EKV. Moreover, the paper shows that the mutant protein is
sequestered in the cytoplasm and does not contribute to
gap junction assembly. Functional studies showing altera-
tion of gap junction function were not performed. As stated
above, incorporation into a gap junction and alteration of its
function or, alternatively, interference with the composition
of the gap junction seem to be required for causation of a
skin phenotype. Also, the absence of a gap junction protein
does not necessarily have functional consequences. We
have shown that connexin 30.3 (GJB4) is not required for
skin function at all. Dominant point mutations in GJB4
cause EKV but homozygosity for a 4 bp-deletion in GJB4
appears to be a polymorphism, at least in the Dutch pop-
ulation (Macari et al, 2000; Van Geel et al, 2002). The po-
lymorphism is rare, underscoring the need for screening of a
sufficient number of controls. We note that Terrinoni et al do
not mention the number of controls used to exclude E100K
as a polymorphism. Finally, conservation of residues in
gap junctions is not a guarantee for their functional impor-
tance. The conserved arginine at position 32 in GJB4
can apparently be substituted by a tryptophan without
adverse consequences, as this change has been demon-
strated to be a polymorphism in Spanish and Dutch pop-
ulations (Lopez-Bigas et al, 2001; Van Geel et al, 2002). It
was also demonstrated that this polymorphism does not
lead to functional impairment of gap junctions (Rouan et al,
2003). In conclusion, the available functional data suggest
that gap junction mutants that cause skin disease seem
to be causing symptoms through a gain-of-function mech-
anism that requires incorporation of the mutant into a
gap junction.
Another concern is with the correctness of the clinical
diagnosis. The photographs accompanying the paper show
abnormalities that in our view could also be consistent with
the diagnosis of cyclic hyperkeratosis with ichthyosis as
described by Sybert et al (1999). A hallmark feature of this
particular disorder is an epidermolytic hyperkeratosis.
Looking at the histology depicted in Fig 1c of the paper,
there is a definite indication of epidermolysis there, partic-
ularly in the suprabasal layer, where cytolysis of keratin-
ocytes also seems to be present. This may also be an
artifact, but other features of EKV such as elongation of rete
ridges seem to be absent. There seems to be some hyper-
granularity of the granular layer but at the magnification and
quality provided it is not possible to discern whether actual
clumping of tonofilaments is present. Electron microscopy
would be helpful in this regard. The clinical appearance of
cyclic hyperkeratosis is also quite similar to that of EKV as
evident from Fig 3 in the Sybert et al paper. This keratinAbbreviation: EKV, erythrokeratodermia variabilis
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disease leads to migrating, erythematous, and sharply de-
marcated plaques that mimic EKV. It would be important to
know whether Terrinoni’s patient had any blistering shortly
after birth as this symptom can distinguish the two dis-
orders. As it is, we are not convinced that the diagnosis
EKV would be the correct one in the patient described by
Terrinoni et al. The diagnosis of cyclic ichthyosis with
epidermolytic hyperkeratosis seems more likely. We sug-
gest that the present case of EKV be tested for KRT1 mu-
tations. It is conceivable that testing of cases of apparent
EKV without mutations in GJB3 or 4 will reveal several KRT1
mutations.
A recessive mutation associated with a skin disease
would be a significant finding. We feel that the present case
report raises sufficient concerns to suggest that the further
confirmatory studies are required. First of all, we would
suggest that a KRT1 mutation be ruled out. Second, if the
diagnosis of EKV can be maintained, the E100K mutation
needs to be confirmed as such by testing an adequate
number of controls and with functional studies. It would be
of interest to examine whether the mutation influences the
expression or transport of other skin-expressed connexins
in any way and impairs gap junction functionality if inserted
into the membrane. Until these concerns are addressed, we
feel that there is insufficient evidence to accept the exist-
ence of recessive EKV caused by a homozygous E100K
substitution.
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